|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.220 SEK | +0.91% |
|
-2.63% | -1.77% |
| 04-21 | Larkberget to carry out rights issue of units totaling SEK 14.9 mln | RE |
| 04-17 | Larkberget net asset value per share at SEK 3.04 | RE |
Company Valuation: CombiGene AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 157.3 | 225.7 | 180.9 | 53.27 | 47.13 | 44.75 |
| Change | - | 43.52% | -19.87% | -70.55% | -11.52% | -5.04% |
| Enterprise Value (EV) 1 | 108.4 | 88.99 | 49.11 | -48.17 | -26.62 | 38.91 |
| Change | - | -17.9% | -44.82% | -198.1% | 44.74% | 246.16% |
| P/E | -4.17x | 9.42x | -29.4x | -1.49x | -1.05x | -3.62x |
| PBR | 2.2x | 1.43x | 1.19x | 0.46x | 0.66x | 0.81x |
| PEG | - | -0x | 0x | -0x | -0x | 0x |
| Capitalization / Revenue | 14.5x | 2.48x | 6.3x | 7.6x | 23.6x | 147x |
| EV / Revenue | 10x | 0.98x | 1.71x | -6.87x | -13.3x | 128x |
| EV / EBITDA | -4.45x | 3.84x | -2.83x | 1.34x | 0.83x | -5.41x |
| EV / EBIT | -4.03x | 3.89x | -2.78x | 1.33x | 0.7x | -3x |
| EV / FCF | -3.73x | 6.84x | -4.04x | 2.57x | 1.54x | -3.65x |
| FCF Yield | -26.8% | 14.6% | -24.7% | 39% | 65.1% | -27.4% |
| Dividend per Share 2 | - | - | - | - | 0.2 | 2 |
| Rate of return | - | - | - | - | 8.4% | 88.5% |
| EPS 2 | -3.287 | 1.21 | -0.3109 | -1.801 | -2.27 | -0.6242 |
| Distribution rate | - | - | - | - | -8.81% | -320% |
| Net sales 1 | 10.83 | 91.15 | 28.73 | 7.008 | 1.999 | 0.304 |
| EBITDA 1 | -24.37 | 23.19 | -17.36 | -35.98 | -32.12 | -7.187 |
| EBIT 1 | -26.87 | 22.89 | -17.66 | -36.31 | -37.92 | -12.98 |
| Net income 1 | -29.38 | 20.96 | -6.157 | -35.67 | -44.88 | -12.36 |
| Net Debt 1 | -48.9 | -136.7 | -131.8 | -101.4 | -73.75 | -5.842 |
| Reference price 2 | 13.720 | 11.400 | 9.135 | 2.690 | 2.380 | 2.260 |
| Nbr of stocks (in thousands) | 11,464 | 19,801 | 19,801 | 19,801 | 19,801 | 19,801 |
| Announcement Date | 04/05/21 | 27/04/22 | 26/04/23 | 26/04/24 | 12/05/25 | 02/04/26 |
1SEK in Million2SEK
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 4.49M | |
| 33.56x | 8.38x | 25.87x | 0.05% | 57.28B | |
| 20.68x | 6.37x | 13.94x | 1.54% | 54.99B | |
| -41.86x | 13.29x | -39.17x | -.--% | 23.18B | |
| -17.88x | 4.15x | -7.26x | -.--% | 22.59B | |
| 25.74x | 5.04x | 13.35x | -.--% | 20.46B | |
| 24.54x | 4.77x | 15.5x | -.--% | 17.56B | |
| -787.21x | 37.41x | -4211.77x | -.--% | 15.67B | |
| 43.58x | 17.61x | 45.34x | 0.08% | 14.46B | |
| 17.42x | 5.04x | 11.77x | -.--% | 13.92B | |
| Average | -75.71x | 11.34x | -459.16x | 0.19% | 24.01B | |
| Weighted average by Cap. | -36.72x | 9.70x | -264.23x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LARK Stock
- Valuation CombiGene AB
Select your edition
All financial news and data tailored to specific country editions
